BIOCON / Q3-FY26 / claim-ledger

Audit the questions that mattered.

Biocon · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ3-FY26 · 2026-02-10Back to quarter ↗

Questions audited

Answered directly

75%

Numeric claims

Consistency

contradicted

Question ledger

What was answered, and how?

Niha Manpurya · Buffa Securities

partial

Is the biosimilar production upgrade behind us and what caused it?

What we've done in the current quarter which was a planned operation where we've upgraded our facilities to be able to scale up uh and uh be able to deliver on this increased demand uh as we go along.

Niha Manpurya · Buffa Securities

evasive

Should biosimilar growth return to 20%+ with mid-20s margins next year?

I've refrained from giving specific guidance uh for the future uh we did say that we will have the mid20s for the current financial year.

Niha Manpurya · Buffa Securities

direct

What will capex be for FY26 and FY27, and will it moderate?

At a group level, we were tracking roughly $275 million plus NIH to recollect uh of capex every year that has been moderated to less than 225 and going forward as the Malaysian capacity buildup gets over I think we will see further moderation.

Damyanti Keral · HSBC Securities

partial

Why did other operating expenses jump 10% sequentially and future trajectory?

That comprises the expenditure across manufacturing facilities, quality expenses, commercial expenses across three entities and uh that is largely fixed in nature. The growth of that particular line uh will be lower than the revenue growth.

Damyanti Keral · HSBC Securities

direct

What is the net debt position as of December 31st?

The net debt that we owe to the bond holders and the banks it's in a very shift in a narrow range of 1.1 to 1.2 billion.

Damyanti Keral · HSBC Securities

direct

Rationale for acquiring full global rights for adalimumab despite US challenges?

It continues to be one of our products that delivers in excess of $200 million for us on an annual basis. So, Adelimo Mab Julio is a very successful franchise for us.

Sham Shri Nasan · Goldman Sachs Research

partial

What drives confidence in higher biologics growth despite 9-month 17% growth?

We've clearly bought five new products. You've seen the uptick of Yeshu in the US seeing a tremendous response. We've seen over 70% formulary coverage.

Sham Shri Nasan · Goldman Sachs Research

partial

Breakdown of generics business growth and outlook?

The growth was driven primarily by LRA glutide launch in European markets. We will be launching this product in few more European countries. In fourth quarter we will also be supplying more product to our partner.

Tushar Manuhan · Moal mentions

direct

What is holding Health Canada from approving GLP1 biosimilars?

Health Canada has not approved a single file they are I think still trying to understand the risk associated with this product. We have done back and forth with health Canada on our previous filing of LIA glutide.

Harshett Dud · Diamond Asia Capital

direct

Is the 700 cr biosimilar EBITDA including exceptional gain?

No harsh that gain is in the exceptional line. It's not part of the ordinary business. So 700 cr is the clean aida kada.

Harshett Dud · Diamond Asia Capital

direct

What drove the sequential EBITDA improvement in biosimilars despite lower revenue?

This quarter we have prioritized high margin markets. So usually the North American geography mix of total biosumas is roughly 40. This quarter is you know it's beyond 46 47.

Vipul Kumar Sha · Individual investor

direct

Name the four molecules with $200M+ revenue and status of oral insulin program?

Zumap fake field grass team insulin franchise including gladene and adali mumap. These are the four molecules which have crossed 200 million in fi25. As far as oral insulin is concerned uh physiologically it worked but financially it didn't make sense.